Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
GAITHERSBURG, Md., Aug. 02, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its second quarter 2017 financial results after close of market on Tuesday, August 8, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and business progress.
Dial-in Information
U.S. Dial-In Number: (888) 883-4599
International Dial-In Number: (484) 653-6821
Conference ID: 61883667
Replay Dial-in Information
U.S. Dial-In Number: (855) 859-2056
International Dial-In Number: (404) 537-3406
Conference ID: 61883667
The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available after the conclusion of the call and will be archived on the company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor Contact: LHA Investor Relations Kim Sutton Golodetz 212-838-3777 [email protected] or Bruce Voss 310-691-7100 [email protected]
